Verrica Pharmaceuticals (VRCA) IPO Opens 33%

Today's IPO for Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) opened for trading at $20 after pricing 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

BofA Merrill Lynch, Jefferies and Cowen are serving as joint book-running managers for the offering.

Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.

You May Also Be Interested In

• Karman Line Acquisition closes $200M IPO on Nasdaq
• EShallGo closes $1.75M registered direct offering at $1 per share
• Jefferies Upgrades Fortescue Metals Group Ltd. (FMG:AU) (FSUGY) to Hold